# Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

> **NCT03323034** · PHASE1 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 30 (actual)

## Conditions studied

- Recurrent Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Primary Central Nervous System Neoplasm
- Refractory Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Primary Central Nervous System Neoplasm

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Pevonedistat
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03323034
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-11
- **Primary completion:** 2021-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03323034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03323034, "Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03323034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*